{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-039517","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.137624+00:00","generated_at":"2026-06-08T21:30:00.328876+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Indaptus Q3 2023 net loss $0.47/share; cash $16M into Q2 2024; Decoy20 all 4 patients stable disease","bullets":["Cash and equivalents $16.0M as of Sep 30, 2023, down from $26.4M at Dec 31, 2022; runway into Q2 2024.","Net loss per share $0.47 for Q3 2023 versus $0.42 year ago; R&D expense $2.2M (up $0.6M YoY).","Decoy20 Phase 1 first cohort: all four patients maintain stable disease; first patient dosed in second cohort.","Roger Waltzman, M.D. appointed Chief Medical Officer effective August 7, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-039517","json":"https://secwatch.observer/filing/0001493152-23-039517.json","markdown":"https://secwatch.observer/filing/0001493152-23-039517.md","text":"https://secwatch.observer/filing/0001493152-23-039517.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223039517/0001493152-23-039517-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223039517/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:30:00.328876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2fa120133c7a25c012010234a84f2701d1f8596d","claim":"Indaptus Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: EPS approximately $0.47.","evidence_excerpt":"On November 6, 2023, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1857044/000149315223039517/0001493152-23-039517-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"EPS","value":"approximately $0.47"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}